Cartesian Therapeutics (RNAC) Cash from Financing Activities (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Cash from Financing Activities of $15.7 million for Q1 2026, up 295.28% year-over-year from $4.0 million in Q1 2025, and up 30236.54% quarter-over-quarter from -$52000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Cash from Financing Activities data on file, last reported at $15.7 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $15.7 million, up 295.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.6 million (down 86.67% YoY), and the FY2025 annual result was -$8.1 million, down 104.78% from the prior year.
- Cash from Financing Activities climbed to $15.7 million in Q1 2026 per RNAC's latest filing, from -$52000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $124.5 million in Q3 2024 and troughed at -$24.8 million in Q3 2023.
- A 5-year average of $12.6 million and a median of $380500.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities tumbled 4150.49% in 2023, then soared 28779.87% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $612000.0 in 2022, then jumped by 2200.82% to $14.1 million in 2023, then plunged by 94.44% to $783000.0 in 2024, then plunged by 106.64% to -$52000.0 in 2025, then soared by 30236.54% to $15.7 million in 2026.
- Business Quant data shows RNAC's Cash from Financing Activities at $15.7 million in Q1 2026, -$52000.0 in Q4 2025, and -$38000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | 15.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.67 Mn |
| Mar 31, 2026 | 15.67 Mn |
| Dec 31, 2025 | -52,000.00 |
| Dec 31, 2025 | -52,000.00 |
| Sep 30, 2025 | -38,000.00 |
| Sep 30, 2025 | -38,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | -8.03 Mn |
| Mar 31, 2025 | -8.03 Mn |
| Dec 31, 2024 | 783,000.00 |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 124.49 Mn |
| Sep 30, 2024 | 124.49 Mn |
| Jun 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 43.03 Mn |
| Mar 31, 2024 | 43.03 Mn |
| Dec 31, 2023 | 14.08 Mn |
| Dec 31, 2023 | 14.08 Mn |